Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec – A Sweet Life



BusinessWeek
Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec
A Sweet Life
by the US Food and Drug Administration. These new insulin analogs have been developed for the treatment of people with type 1 and type 2 diabetes. As with the European applications submitted on September 26, the US filings are based on results from the
Novo Nordisk Files For US Approval Of New Insulin DrugsFox Business
Danish Novo Nordisk applies for approval of two diabetes drugs in USAMiddle East North Africa Financial Network
Upscale Insulin Gets a ShotBusinessWeek
RTT News -Daily Markets
all 12 news articles »

Diabetes – Google News